Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TuHURA Biosciences ( (HURA) ) has shared an announcement.
On October 27, 2025, TuHURA Biosciences entered into a Secured Promissory Note and Loan Agreement with the Matthew Nachtrab Revocable Trust for a bridge loan of up to $3,000,000 to be used for working capital. The loan is secured by U.S. patents related to TuHURA’s ImmuneFxTM technology and includes the issuance of warrants to purchase common stock, reflecting a strategic move to bolster financial resources and potentially enhance its market position.
The most recent analyst rating on (HURA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
Spark’s Take on HURA Stock
According to Spark, TipRanks’ AI Analyst, HURA is a Underperform.
TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company’s poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.
To see Spark’s full report on HURA stock, click here.
More about TuHURA Biosciences
TuHURA Biosciences, Inc. operates in the biotechnology industry, focusing on developing innovative solutions, including its ImmuneFxTM technology platform.
Average Trading Volume: 392,623
Technical Sentiment Signal: Strong Sell
Current Market Cap: $126.7M
See more insights into HURA stock on TipRanks’ Stock Analysis page.